CPT-SIOP-2000

CPT-SIOP-2000 Treatment of tumors of the choroid plexus epithelium. An intercontinental phase III chemotherapy study for patients with choroid plexus tumors
Erkrankung Tumoren des Plexus choroideus
Einschluss-Kriterien
  • Eligibility criteria for first registration (registration and follow-up study)
  • Histological diagnosis of a choroid plexus tumor by a local pathologist / neuropathologist. This includes choroid plexus papilloma, atypical choroid plexus papilloma, anaplastic choroid plexus papilloma, malignant choroid plexus papilloma, and choroid plexus carcinoma. WHO brain tumor classification 1.5.1 and 1.5.2 (Kleihues 1993), ICD-O classification M-9390/0, M-9390/3 (WHO 1990)
  • Slides have been sent to the pathology reference centre (by declaration of the sending centre)
  • Eligibility criteria for registration for randomization (center depended voluntary second registration or treatment study)
  • The first registration on the study was completed
  • The reference centre has confirmed the receipt of slides sent
  • The postoperative imaging has been done and the result is available
  • The indication criteria (Table 2) are met
  • The chemotherapy start criteria (Table 3) are met
  • The agreement of patient or legal guardian has been documented according to the local guidelines
Ausschluss-Kriterien
  • Patient or legal guardian does not consent to enrollment with electronic data processing or sending of tumor slides to the pathology reference centre
Status Beginn 28.10.2000 Ende 12.03.2010
Leiter Prof. Dr. med. Johannes E. A. Wolff
E-Mail jwolff@mdanderson.org
Kontakt

Nationaler Studienleiter Deutschland

PD Dr. med. Uwe Richard Kordes Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik f. Päd. Hämatologie u. Onkologie Martinistraße 52 20246 Hamburg Telefon +49 (40) 7410 59199 Fax +49 (40) 7410-57544

Studienzentrale

cpt@uke.de

Weitere Informationen Die Studie wurde am 12.03.2010 beendet. Im Sommer 2010 ist der Beginn eines CPT-Registers geplant.
Verweis(e) Geschützte Dokumente
Förderung Deutsche Kinderkrebsstiftung (Bonn)